Show simple item record

dc.contributor.authorPugh, SA
dc.contributor.authorBowers, M
dc.contributor.authorBall, A
dc.contributor.authorFalk, S
dc.contributor.authorFinch-Jones, M
dc.contributor.authorValle, JW
dc.contributor.authorO'Reilly, DA
dc.contributor.authorSiriwardena, AK
dc.contributor.authorHornbuckle, J
dc.contributor.authorRees, M
dc.contributor.authorRees, C
dc.contributor.authorIveson, T
dc.contributor.authorHickish, T
dc.contributor.authorMaishman, T
dc.contributor.authorStanton, L
dc.contributor.authorDixon, E
dc.contributor.authorCorkhill, A
dc.contributor.authorRadford, M
dc.contributor.authorGarden, OJ
dc.contributor.authorCunningham, D
dc.contributor.authorMaughan, TS
dc.contributor.authorBridgewater, JA
dc.contributor.authorPrimrose, JN
dc.date.accessioned2017-03-27T12:32:54Z
dc.date.issued2016-08
dc.identifier.citationBritish journal of cancer, 2016, 115 (4), pp. 420 - 424
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/535
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/bjc.2016.208
dc.description.abstractBackground The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further inform the primary study outcome.Methods A total of 257 KRAS wild-type patients were randomised to CT alone or CT with CTX. Data regarding sites and treatment of progressive disease were obtained for the 109 (CT n=48, CT and CTX n=61) patients with progressive disease at the cut-off date for analysis of November 2012.Results The liver was the most frequent site of progression (CT 67% (32/48); CT and CTX 66% (40/61)). A higher proportion of patients in the CT and group had multiple sites of progressive disease (CT 8%, 4/48; CT and CTX 23%, 14/61 P=0.04). Further treatment for progressive disease is known for 84 patients of whom 69 received further CT, most frequently irinotecan based. Twenty-two patients, 11 in each arm, received CTX as a further line agent.Conclusions Both the distribution of progressive disease and further treatment are as expected for such a cohort. The pattern of disease progression seen is consistent with failure of systemic micrometastatic disease control rather than failure of local disease control following liver surgery.
dc.formatPrint-Electronic
dc.format.extent420 - 424
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectColorectal Neoplasms
dc.subjectLiver Neoplasms
dc.subjectDisease Progression
dc.subjectOrganoplatinum Compounds
dc.subjectCamptothecin
dc.subjectLeucovorin
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDisease-Free Survival
dc.subjectNeoadjuvant Therapy
dc.subjectHepatectomy
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectMetastasectomy
dc.subjectCapecitabine
dc.subjectCetuximab
dc.subjectIrinotecan
dc.subjectOxaliplatin
dc.titlePatterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
dc.typeJournal Article
dcterms.dateAccepted2016-06-13
rioxxterms.versionofrecord10.1038/bjc.2016.208
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-sa/4.0
rioxxterms.licenseref.startdate2016-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of cancer
pubs.issue4
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume115en_US
pubs.embargo.terms12 months
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, Daviden


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record